RESUMO
In 1990, Saudi Arabia began vaccinating all children at school entry against hepatitis B. We evaluated hepatitis B surface antigen (HBsAg) prevalence rate among pregnant Saudi women 12 years later in 5 regions of the country. Using multistage sampling, 2664 pregnant Saudi women were recruited. Blood samples were tested for HBsAg; positive samples were also tested for hepatitis Be antigen (HBeAg). In all 2.44% were positive for HBsAg and 4 (0.15%) were also positive for HBeAg. HBsAg prevalence was highest in Gizan (4.2%) and lowest in Tabuk (1.4%). Positivity for women < or = 20 years of age was 0.5% compared with 2.6% for older women (P = 0.049). The overall HBsAg prevalence rate was lower than previously reported.
Assuntos
Antígenos de Superfície da Hepatite B/sangue , Hepatite B/epidemiologia , Complicações Infecciosas na Gravidez/epidemiologia , Adulto , Distribuição por Idade , Portador Sadio/epidemiologia , Causalidade , Estudos Transversais , Assistência Odontológica/efeitos adversos , Feminino , Necessidades e Demandas de Serviços de Saúde , Hepatite B/sangue , Hepatite B/imunologia , Hepatite B/prevenção & controle , Antígenos E da Hepatite B/sangue , Humanos , Programas de Rastreamento , Vacinação em Massa/organização & administração , Gravidez , Complicações Infecciosas na Gravidez/sangue , Complicações Infecciosas na Gravidez/imunologia , Complicações Infecciosas na Gravidez/prevenção & controle , Avaliação de Programas e Projetos de Saúde , Características de Residência , Arábia Saudita/epidemiologia , Estudos Soroepidemiológicos , Procedimentos Cirúrgicos Operatórios/efeitos adversos , Reação TransfusionalRESUMO
In 1990, Saudi Arabia began vaccinating all children at school entry against hepatitis B. We evaluated hepatitis B surface antigen [HBsAg] prevalence rate among pregnant Saudi women 12 years later in 5 regions of the country. Using multistage sampling, 2664 pregnant Saudi women were recruited. Blood samples were tested for HBsAg; positive samples were also tested for hepatitis Be antigen [HBeAg]. In all 2.44% were positive for HBsAg and 4 [0.15%] were also positive for HBeAg. HBsAg prevalence was highest in Gizan [4.2%] and lowest in Tabuk [1.4%]. Positivity for women < or = 20 years of age was 0.5% compared with 2.6% for older women [P = 0.049]. The overall HBsAg prevalence rate was lower than previously reported
Assuntos
Distribuição por Idade , Transfusão de Sangue , Portador Sadio , Causalidade , Estudos Transversais , Antígenos de Superfície da Hepatite B , Hepatite BRESUMO
We evaluated the safety of a measles-mumps-rubella (MMR) immunization campaign for Saudi children (age range: 6-13 years) and gender differences in reporting post-MMR adverse events. After vaccinations were administered, we monitored 160 schools for 14 days and 19 hospitals in the 8 cities under study for 10 weeks. Incidence rates were: all MMR adverse events, 26.5/10,000 MMR vaccines (significantly higher in females than males); Urabe strain aseptic meningitis, 1.0/295,000; fever, 40.2/10,000 (females) and 0.9/10,000 (males); and parotitis, 5.4/10,000 (females) and 0.9/10,000 (males). Combined MMR vaccine containing the Urabe mumps strain was safe for children aged 6-13 years. Gender differences regarding reactogenicity were evident and should be considered when designing future studies.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos/normas , Coleta de Dados/normas , Vacina contra Sarampo-Caxumba-Rubéola/efeitos adversos , Adolescente , Índice de Massa Corporal , Criança , Hipersensibilidade a Drogas/epidemiologia , Hipersensibilidade a Drogas/etiologia , Feminino , Febre/epidemiologia , Febre/etiologia , Humanos , Programas de Imunização/organização & administração , Incidência , Masculino , Vacina contra Sarampo-Caxumba-Rubéola/metabolismo , Vacina contra Sarampo-Caxumba-Rubéola/farmacocinética , Meningite Asséptica/epidemiologia , Meningite Asséptica/etiologia , Taxa de Depuração Metabólica , Parotidite/epidemiologia , Parotidite/etiologia , Vigilância da População , Avaliação de Programas e Projetos de Saúde , Fatores de Risco , Segurança , Arábia Saudita/epidemiologia , Caracteres Sexuais , Distribuição por SexoRESUMO
We evaluated the safety of a measles-mumps-rubella [MMR] immunization campaign for Saudi children [age range: 6-13 years] and gender differences in reporting post-MMR adverse events. After vaccinations were administered, we monitored 160 schools for 14 days and 19 hospitals in the 8 cities under study for 10 weeks. Incidence rates were: all MMR adverse events, 26.5/10,000 MMR vaccines [significantly higher in females than males]; Urabe strain aseptic meningitis, 1.0/295,000; fever, 40.2/10,000 [females] and 0.9/10,000 [males]; and parotitis, 5.4/10,000 [females] and 0.9/10,000 [males]. Combined MMR vaccine containing the Urabe mumps strain was safe for children aged 6-13 years. Gender differences regarding reactogenicity were evident and should be considered when designing future studies
